Published in Cancer Weekly, August 4th, 2009
"Two eribulin mesylate phase 1 studies exploring weekly and 3-weekly schedules are reported in this issue. These trials show linear pharmacokinetics, a toxicity profile consisting in neutropenia and fatigue, and early hints of antitumor activity," wrote A. Jimeno and colleagues, University of Colorado.
The researchers concluded: "In this commentary we give a brief historical perspective of the halichondrins and put into context eribulin...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.